Use of linezolid in critically ill patients admitted to Intensive Care Units

Revista Espanola de Quimioterapia

Volumn 22, Issue 2, 2009, Pages 68-75

  Rodríguez Colomo, Oscar ^a   Alvarez F ^b   Oltra, R ^a   Cereijo, E ^c   Latorre, M M ^d   Martinez H ^e  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e Hospital Cruz Roja   (Spain)

Author keywords

Critically ill patient; ICU; Linezolid

Indexed keywords

LINEZOLID; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG TREATMENT FAILURE; FEMALE; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; SOFT TISSUE INFECTION; SURGICAL INFECTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL PNEUMONIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMMUNICABLE DISEASE; CRITICAL ILLNESS; CROSS INFECTION; DISEASE PREDISPOSITION; DRUG EFFECT; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MICROBIOLOGY; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; STATISTICS; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; CRITICAL ILLNESS; CROSS INFECTION; DISEASE SUSCEPTIBILITY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 70349581060     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Asensio A, Cantón R, Vaqué J, Roselló J, Arribas JL. Antimicrobial use in Spanish hospitals (EPINE, 1990-1999). Med Clin (Barc) 2002;118:730-736
2. Alvarez-Lerma F, Palomar M, Olaechea P, Otal JJ, Insausti J, Cerdá E and the Grupo de Estudio de Vigilancia de Infección Nosocomial en UCI. Estudio Nacional de Vigilancia de Infección Nosocomial en Unidades de Cuidados Intensivos. Progress report of years 2003-2005. Med Intensiva 2007;31:6-17.
3. Grupo de Trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina Intensiva (ENVIN-UCI). Report 2006. SEMI-CYUC.
4. Cardo D, Horan T, Andrus M, Dembinski M, Edwards J, Peavy G, et al. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485
5. Grupo VIRA, Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, Gómez M, et al. Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2006. Enferm Infecc Microbiol Clin 2006;24:617-628
6. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Annals of Clinical Microbiology and Antimicrobials 2004;3:14.
7. Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UCI, Álvarez Lerma F, Palomar M, Insausti J, Olaechea P, Cerdá E, et al. Staphylococcus aureus nosocomial infections in critically ill patients admitted in intensive care units. Med Clin (Barc) 2006;126:641-646
8. Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L, Mathema B, et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: Recent clonal expansion and diversification. Proc Natl Acas Scienc USA 2008;105:1323-1332
9. Insausti J. Consumo de antibióticos en medicina intensiva. In: Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Madrid: Jarpyo Editores, S.A.,2002; pp. 129-148
10. Malacarne P, Rossi C, Bertolini G. GiViTI Group. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother 2004;54:221-224 (Pubitemid 39028994)
11. Ziglam HM, Finch RG. Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin Microbiol Infect 2001;7:53-65.
12. Alvarez Lerma F, Palomar M, Bobillo F, González V, Sole J, León C, et al. Linezolid trente a glucopéptidos en el tratamiento de infecciones conocidas o sospechadas por cocos grampositivos en patientes ingresados en UCI. Enferm Infec Microb Clin 2004;22(Suppl. 1):97.
13. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437-451
14. Delgado G Jr, Neuhauser MM, Bearden DT, Danzinger LH. Quinupristin-dalfopristin: an overwiew. Pharmacotherapy 2000;20:1469-1485
15. Marchese A, Schito GC. The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 2001;7(Suppl. 4):66-74.
16. Perry CM, Jarvis B. Linezolid: a review of serious gram-positive infections. Drugs 2001;61:525-551
17. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001;35:566-575
18. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53:345-355
19. Bouza E, Muñoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001;7:75-82. (Pubitemid 34966110)
20. Moise-Broder PA, Forrest A, Birmingham MG, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-942 (Pubitemid 39447034)
21. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869
22. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-160
23. Bingen E, Mariani-Kurkdjian P, Nebbad B. Optimal vancomycin serum level in Staphylococcus aureus infections? Med Mal Infect 2006;36:439-442
24. Stevens DL. The role of vancomycin in the treatment paradigm. CID 2006;42(Suppl. 1):42-47.
25. González C, Rubio M, Romero-Vivas, J González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177 (Pubitemid 30265635)
26. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-Dose Vancomycin Therapy for Methicillin- Resistant Staphylococcus aureus Infections. Arch Intern Med 2006;166:2138-2144
27. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006;28:1208-1216
28. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Veselka P, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteriemia. Clin Infect Dis 2008;46:193-200.
29. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-3886 (Pubitemid 44737223)
30. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-1115 (Pubitemid 47208584)
31. Linezolid Nosocomial Pneumonia Study Group, Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32(3):402-412
32. Linezolid Nosocomial Pneumonia Study Group, Wunderink RG, Cammarata SK, Oliphant TH, Koller MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992
33. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394
34. Paule SM, Pasquariello AC, Thomson RB Jr, Kaul KL Peterson LR. Real-time PCR can rapidly detect methicillin-susceptible and methicillin-resistant Staphylococcus aureus directly from positive blood culture bottles. Am J Clin Pathol 2005;124:404-407
35. Stratidis J, Bia FJ, Edberg SC. Use of real-time polymerase chain reaction for identification of methicillin-resistant Staphylococcus aureus directly from positive blood culture bottles. Diagn Microbiol Infect Dis 2007;15 [Epub ahead of print].
36. Grupo de Estudio de uso de Antibióticos Activos frente a Cocos Gram Positivos Multirresistentes en Pacientes Críticos, Rodríguez-Colomo O, Álvarez-Lerma F. Utilización de antibióticos en el tratamiento de infecciones por cocos grampositivos multirresistentes en pacientes criticos. Med Intensiva 2008 (in press).
37. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-140
38. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874